All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›ARK Invest Europe›AAKG

AAKG

ARK Genomic Revolution UCITS ETF

Active ETF Equity ESG Theme: BioTech & Genomics

Not rated

The AAKG Exchange Traded Fund (ETF) is provided by ARK Invest Europe. This fund is actively managed; it does not track an index. The dividend policy is capitalization.

$9.28

N/A

Data as of 08/27/26

1D price range

N/A

52W price range

$4.59$9.33

YTD Perf.

+71.15%

YTD Flows

Annualized volatility

Fund AuM

€85M

Share class AuM

€85M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE000O5M6XO1

TER

0.75%

Inception date

4/12/2024

Issuer

ARK Invest Europe

Dividend policy

Capitalization

Compare similar ETFs

ETF Name	1w perf.
ARKG ARK Genomic Revolution ETF	-3.82%
XBI State Street SPDR S&P Biotech ETF	-2.02%
CURE Global X S&P Biotech ETF	+2.03%
BBP Virtus LifeSci Biotech Products ETF	-1.48%
XPH State Street SPDR S&P Pharmaceuticals ETF	-2.71%
PTH Invesco DWA Healthcare Momentum ETF	-3.10%
PSCH Invesco S&P SmallCap Health Care ETF	-1.84%
SBIO ALPS Medical Breakthroughs ETF	-2.90%
XHE State Street SPDR S&P Health Care Equipment ETF	-1.67%
BBC Virtus LifeSci Biotech Clinical Trials ETF	-2.19%
IBRN iShares Neuroscience and Healthcare ETF	-1.09%
FMED Fidelity Disruptive Medicine ETF	-2.94%
HELX Franklin Genomic Advancements ETF	-2.53%
GNOM Global X Genomics & Biotechnology ETF	-2.72%
GNOG Global X Genomics & Biotechnology UCITS ETF	-2.71%

API

PerformanceDec 31, 2025 - Aug 27, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 07/31/26

Healthcare

100.00%

Latest AAKG news

Biotech ETFs See Uptick Amid Positive Market Signs

Smart Investing · July 16, 2024

FAQ about AAKG

AAKG is a Active ETF. This ETF provides exposure to Other Equities.

AAKG carries a total expense ratio (TER) of 0.75%, indicating the annual cost for holding the fund.

AAKG was introduced to the market on April 12, 2024. It trades on United Kingdom, among other exchanges

ARK Genomic Revolution UCITS ETF, AAKG, is provided by ARK Invest Europe. Learn more about ARK Invest Europe here.

AAKG oversees €85M in assets as of August 27, 2026.

AAKG follows a capitalizing, meaning it reinvests income within the fund.

As of July 31, 2026, AAKG has significant geographic allocations in USA, Switzerland and United Kingdom.

As of July 31, 2026, AAKG focuses largely on Healthcare.

As of July 31, 2026, AAKG holds 31 positions in its portfolio, with 73.14% of assets concentrated in its top 15 holdings.

As of July 31, 2026, AAKG top three holdings include Twist Bioscience Corp., Tempus AI, Inc. and 10X Genomics, Inc..

The base currency of AAKG is USD.

Top 10 holdings

Data as of 07/31/26

Twist Bioscience Corp.

8.59%

Tempus AI, Inc.

6.76%

10X Genomics, Inc.

6.32%

CRISPR Therapeutics AG

6.05%

Eli Lilly & Co.

5.69%

Illumina, Inc.

4.97%

Absci Corp.

4.85%

Personalis, Inc.

4.50%

CareDx, Inc.

4.31%

Natera, Inc.

4.29%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

ARK Genomic Revolution UCITS ETF

FAQ about AAKG

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US